Cancer is the leading cause of death worldwide, and its treatment and outcomes have been
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …

Simple Summary KRAS is the most frequently mutated oncogene in non-small cell lung
cancers (NSCLC), with a frequency around 30%, and among them KRAS G12C mutation …

Despite the success of KRAS G12C inhibitors in non–small cell lung cancer (NSCLC), more
effective treatments are needed. One preclinical strategy has been to cotarget RAS and …

Activating KRAS mutations are present in 25% of human cancer. Although oncogenic Ras
was deemed" undruggable" in the past, recent efforts led to the development of …

Simple Summary A better understanding of the role of KRAS and its different mutations has
led to the development of specific small-molecule inhibitors able to target KRAS G12C, an …

KRAS mutation is one of the most prevalent genetic drivers of cancer development, yet
KRAS mutations are until very recently considered undruggable. There are ongoing trials of …

Simple Summary Pancreatic ductal adenocarcinoma is one of the deadliest malignancies in
humans. Despite advances in systemic therapy, prognosis still remains poor. However …

Glycogen synthase kinase (GSK) 3β is a multifunctional serine/threonine protein kinase with
more than 100 substrates and interacting molecules. GSK3β is normally active in cells and …

The function and significance of RAS proteins in cancer have been widely studied for
decades. In 2013, the National Cancer Institute established the RAS Initiative to explore …

Tumor biomarkers, the substances which are produced by tumors or the body's responses to
tumors during tumorigenesis and progression, have been demonstrated to possess critical …